Complete Filing Data
BELITE BIO, INC reported Stockholders Equity of $770.49 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean BELITE BIO, INC did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$77.6M | -$36.1M | -$31.6M | -$12.6M | -$9.7M | -$5.8M |
| Research And Development Expense | $45.4M | $29.9M | $24.8M | $8.9M | $7.4M | $3.7M |
| Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | $124.0K | -$286.0K | $18.0K | -$196.0K | -$152.0K | $6.0K |
| Operating Income Loss | -$84.2M | -$40.0M | -$31.7M | -$12.8M | -$9.8M | -$5.7M |
| Operating Expenses | $84.2M | $40.0M | $31.7M | $12.8M | $9.8M | $5.7M |
| Nonoperating Income Expense | $6.6M | $3.9M | $45.0K | $173.0K | $131.0K | -$9.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$77.6M | -$36.1M | -$31.6M | -$12.6M | -$9.7M | -$5.8M |
| Comprehensive Income Net Of Tax | -$77.5M | -$36.4M | -$31.6M | -$12.8M | -$9.8M | -$5.7M |
| Other Nonoperating Income Expense | -$41.0K | $141.0K | -$4.0K | $166.0K | $126.0K | |
| General And Administrative Expense | $10.1M | $6.8M | $4.0M | $2.4M | $2.1M | |
| Income Tax Expense Benefit | $0.00 | $6.0K | $9.0K | $1.0K | ||
| Interest Expense Nonoperating | $2.0K | $20.0K | $25.0K | $16.0K | ||
| Income Taxes Paid Net | $6.0K | $9.0K | ||||
| Interest Expense | $25.0K | $16.0K | $21.0K | |||
| Selling General And Administrative Expense | $38.8M | $10.1M | $6.8M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $770.5M | $145.8M | $90.4M | $41.5M | -$15.1M | -$7.0M | -$3.7M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $352.9M | $31.7M | $88.2M | $42.1M | $17.3M | $25.6M | $2.0M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $321.3M | -$56.5M | $46.1M | $24.7M | -$8.3M | $23.6M | |
| Operating Lease Right Of Use Asset Amortization Expense | $280.0K | $281.0K | $260.0K | $134.0K | $0.00 | ||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $529.0K | $388.0K | $265.0K | $941.0K | |||
| Retained Earnings Accumulated Deficit | -$185.3M | -$107.6M | -$71.5M | -$39.9M | -$27.2M | -$17.6M | |
| Operating Lease Payments | $301.0K | $305.0K | $244.0K | $71.0K | |||
| Property Plant And Equipment Net | $344.0K | $444.0K | $490.0K | $541.0K | $94.0K | ||
| Prepaid Expense And Other Assets Current | $1.2M | $1.3M | $947.0K | $716.0K | $87.0K | ||
| Operating Lease Right Of Use Asset | $433.0K | $521.0K | $811.0K | $806.0K | $941.0K | ||
| Liabilities Current | $9.9M | $6.1M | $3.6M | $2.1M | $1.6M | ||
| Liabilities And Stockholders Equity | $780.6M | $152.1M | $94.6M | $44.3M | $18.3M | ||
| Liabilities | $10.1M | $6.3M | $4.2M | $2.8M | $1.6M | ||
| Deposits Assets Noncurrent | $253.0K | $103.0K | $104.0K | $88.0K | $8.0K | ||
| Common Stock Value | $4.0K | $3.0K | $3.0K | $3.0K | $1.0K | ||
| Cash And Cash Equivalents At Carrying Value | $352.9M | $31.7M | $88.2M | $42.1M | $17.3M | ||
| Assets Current | $494.3M | $147.1M | $89.9M | $42.8M | $17.4M | ||
| Assets | $780.6M | $152.1M | $94.6M | $44.3M | $18.3M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$536.0K | -$660.0K | -$374.0K | -$392.0K | -$196.0K | ||
| Accrued Liabilities Current | $9.6M | $5.8M | $3.3M | $1.9M | $1.6M | ||
| Operating Lease Liability Noncurrent | $188.0K | $261.0K | $578.0K | $668.0K | |||
| Operating Lease Liability Current | $241.0K | $276.0K | $308.0K | $198.0K | |||
| Prepaid Expense And Other Assets Noncurrent | $4.0M | $3.3M | $31.0K | ||||
| Right Of Use Asset Obtained In Exchange Of Lease Liabilities From Operating Lease Modification | $361.0K | $385.0K | |||||
| Other Liabilities Current | $5.0K | $13.0K | |||||
| Intangible Assets Net Excluding Goodwill | $19.0K | $31.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $38.9M | $9.0M | $3.8M | $1.5M | $1.5M | $1.4M |
| Proceeds From Stock Options Exercised | $7.8M | $2.8M | $349.0K | $3.0K | $232.0K | $86.0K |
| Net Cash Provided By Used In Operating Activities | -$37.0M | -$29.2M | -$29.8M | -$11.5M | -$7.5M | -$4.4M |
| Net Cash Provided By Used In Investing Activities | -$305.1M | -$110.6M | -$63.0K | -$394.0K | -$56.0K | -$20.0K |
| Net Cash Provided By Used In Financing Activities | $663.2M | $83.6M | $76.0M | $37.0M | -$583.0K | $28.1M |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $3.8M | $2.5M | $1.4M | $373.0K | $632.0K | -$254.0K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $117.0K | -$269.0K | $9.0K | -$366.0K | -$161.0K | $4.0K |
| Payments To Acquire Property Plant And Equipment | $71.0K | $116.0K | $63.0K | $394.0K | $74.0K | |
| Increase Decrease In Deposit Other Assets | $150.0K | $16.0K | $79.0K | $2.0K | -$8.0K | |
| Increase Decrease In Prepaid Expense | $1.1M | $3.5M | $641.0K | $35.0K | -$192.0K | |
| Increase Decrease In Due To Related Parties | -$8.0K | $13.0K | -$41.0K | $45.0K | -$19.0K | |
| Increase Decrease In Due From Related Parties Current | -$18.0K | $16.0K | $32.0K | -$4.0K | ||
| Proceeds From Warrant Exercises | $103.0M | $39.0M | $21.7M | |||
| Increase Decrease In Other Receivables | $66.0K | -$56.0K | $56.0K | |||
| Payments Of Stock Issuance Costs | $1.0M | $815.0K | ||||
| Proceeds From Issuance Initial Public Offering | $38.0M | |||||
| Payments To Acquire Held To Maturity Securities | $452.0M | $183.8M | ||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $768.0K | $1.1M | $3.5M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 33.5M | 30.5M | 26.6M | 20.0M | 9.6M | 8.8M |
| Weighted Average Number Of Diluted Shares Outstanding | 33.5M | 30.5M | 26.6M | 20.0M | 9.6M | 8.8M |
| Earnings Per Share Diluted | $-2.31 | $-1.18 | $-1.19 | $-0.63 | $-1.01 | $-0.65 |
| Earnings Per Share Basic | $-2.31 | $-1.18 | $-1.19 | $-0.63 | $-1.01 | $-0.65 |
| Common Stock Shares Outstanding | 39.3M | 31.8M | 29.1M | 24.9M | 10.3M | |
| Common Stock Shares Issued | 39.4M | 31.9M | 29.2M | 24.9M | 10.3M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Authorized | 400.0M | 400.0M | 400.0M | 492.2M | 492.2M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $7.8M | $2.8M | $349.0K | $3.0K | $232.0K | $86.0K |
| Investment Income Interest | $6.6M | $3.7M | $74.0K | $23.0K | $5.0K | $12.0K |
| Depreciation | $172.0K | $164.0K | $139.0K | $64.0K | $30.0K | $17.0K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $38.9M | $9.0M | $3.8M | $1.5M | $1.5M | $1.4M |
| Additional Paid In Capital | $956.3M | $254.1M | $162.3M | $81.8M | $12.3M | |
| Stock Issued During Period Value Warrant Exercises | $103.0M | $39.0M | $21.7M | |||
| Class Of Warrant Or Right Exercised | $1.5M | $1.4M | $1.2M | |||
| At Market Offering Sales Commission Reclassed To Additional Paid In Capital | -$896.0K | -$509.0K | -$858.0K | |||
| Interest Paid Net | $1.0K | $16.0K | $19.0K | |||
| Stock Issued During Period Value New Issues | $36.1M | $500.0K | ||||
| Interest Income From Investment | $1.3M | $3.6M |
Most recent annual filing with the SEC: March 31, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.